Keywords: Tumors (Post-Treatment), Neuro
Motivation: Distinguishing tumor progression from treatment response, following brain tumor therapy remains a major clinical challenge.
Goal(s): To assess the diagnostic performance of fluid suppressed amide proton transfer-weighted (FS-APTW) imaging in distinguishing true progression from treatment response with post-treatment gliomas.
Approach: We conducted APTW and FS-APTW imaging on 66 patients with post-treatment gliomas. The APTWmean and FS-APTWmean signals were obtained from enhanced lesions and peritumoral edema for each patient and compared between the true progression and treatment response groups.
Results: The FS-APTW signal is a valuable imaging biomarker for distinguishing treatment response from true progression in post-treatment gliomas.
Impact: FS-APTW imaging offers a more specific characterization of true progression versus treatment response in post-treatment gliomas than APTW imaging.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords